Inflammation and myocardial damage markers influence loss of residual renal function in peritoneal dialysis patients

Archives of Medical Research

Volumn 45, Issue 6, 2014, Pages 484-488

  Palomo Piñón, Silvia ^a   Mora Villalpando, Carmen Josefina ^a   Del Carmen Prado Uribe, Ma ^a   Ceballos Reyes, Guillermo Manuel ^b   De Jesús Ventura García, Ma ^a   Ávila Díaz, Marcela ^a   Rodríguez, Oscar Orihuela ^a   Paniagua Sierra, José Ramón ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Cardiorenal syndromes; Inflammation; Myocardial damage; Peritoneal dialysis; Residual renal function

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; SERUM ALBUMIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIORENAL SYNDROME; COHORT ANALYSIS; COMORBIDITY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE INJURY; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; AGED; BLOOD; CLINICAL TRIAL; FOLLOW UP; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIO-RENAL SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84908066238     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.07.003     Document Type: Article

References (29)

1. Eknoyan G., Beck G.J., Cheung A.K., et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002, 347:2010-2019.
2. Paniagua R., Amato D., Vonesh E., et al. Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002, 13:1307-1320.
3. Wang A.Y., Lai K.N. The importance of residual renal function in dialysis patients. Kidney Int 2006, 69:1726-1732.
4. Van Biesen W., Lameire N., Verbeke F., et al. Residual renal function and volume status in peritoneal dialysis patients: a conflict of interest?. J Nephrol 2008, 21:299-304.
5. Hidaka H., Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology (Carlton) 2003, 8:184-191.
6. Bakris G.L., Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Am Soc Hypertens 2009, 3:80-83. World Kidney Day Steering Committee.
7. Ronco C., Di Lullo L. Cardiorenal syndrome. Heart Failure Clin 2014, 10:251-280.
8. Coronel F., Pérez-Flores I., Calvo N., et al. Impact of cardiovascular events on residual renal function during the first year of peritoneal dialysis. Perit Dial Int 2007, 27:454-456.
9. Medcalf J.F., Harris K.P., Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001, 59:1128-1133.
10. Moist L.M., Port F.K., Orzol S.M., et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000, 11:556-564.
11. Paniagua R., Amato D., Correa-Rotter R., et al. Correlation between the peritoneal equilibration test and the dialysis adequacy and transport test for peritoneal transport type characterization. Perit Dial Int 2000, 20:53-59.
12. Sokolow M., Lyon T.P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949, 37:161-186.
13. Li P.K., Chow K.M. Infectious complications in dialysis-epidemiology and outcomes. Nat Rev Nephrol 2012, 8:77-88.
14. Liao C.T., Shiao C.C., Huang J.W., et al. Predictors of faster decline of residual renal function in Taiwanese peritoneal dialysis patients. Perit Dial Int 2008, 28(suppl 3):S191-S195.
15. Li P.K., Chow K.M., Wong T.Y., et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis: a randomized, controlled study. Ann Intern Med 2003, 139:105-112.
16. Wong T.Y., Szeto C.C., Chow K.M., et al. Prognostic role of serum ACE activity on outcome of type 2 diabetic patients on chronic ambulatory peritoneal dialysis. Am J Kidney Dis 2002, 39:1054-1060.
17. Hufnagel G., Michel C., Queffeulou G., et al. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999, 14:1224-1228.
18. Lysaght M.J., Vonesh E.F., Gotch F., et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991, 37:598-604.
19. Jansen M.A., Hart A.A., Korevaar J.C., et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002, 62:1046-1053.
20. Vickery S., Price C.P., John R.I., et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005, 46:610-620.
21. Haug C., Metzele A., Steffgen J., et al. Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. Horm Metab Res 1994, 26:246-249.
22. Gangji A.S., Helal B.A., Churchill D.N., et al. Association between N-terminal propeptide B-type natriuretic peptide and markers of hypervolemia. Perit Dial Int 2008, 28:308-311.
23. Paniagua R., Amato D., Vonesh E., et al. Predictive value of natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol 2008, 3:407-415. For the Mexican Nephrology Collaborative Study Group.
24. Paniagua R., Ventura M.D., Ávila-Diaz M., et al. NT-proBNP, fluid volume overload, and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant 2010, 25:551-557.
25. Pecoits-Filho R., Bucharles S., Barberato S.H. Diastolic heart failure in dialysis patients: mechanism, diagnosis approach and treatment. Semin Dial 2012, 25:35-41.
26. Keith D.S., Nichols G.A., Gullion C.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
27. Pecoits-Filho R., Heimbürger O., Bárány P., et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003, 41:1212-1218.
28. Stompór T., Zdzienicka A., Motyka M., et al. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Perit Dial Int 2002, 22:670-676.
29. Khalifeh N., Haider D., Hörl W.H. Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update. J Investig Med 2009, 57:33-39.